Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
NEW YORK, Oct. 26, 2017 -- The Nasdaq Stock Market® (Nasdaq:NDAQ) announced that trading was halted today in INSYS Therapeutics, Inc. (Nasdaq:INSY) at 16:55:13 Eastern Time for "additional information requested" from the company at a last sale price of $5.74.
Trading will remain halted until INSYS Therapeutics, Inc. has fully satisfied Nasdaq’s request for additional information.
For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.
For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.
NDAQO
Nasdaq Media Contact:
Christine Barna
[email protected]
